Opinion of the Transparency Council – on the appropriateness of making changes to the B.111 drug program
At its meeting on 21 October 2024, the Transparency Council adopted opinion No. 167/2024 on the appropriateness of amending the drug program B.111. “Treatment of severe growth hormone deficiency in adult patients and in adolescents after growth-promoting therapy (ICD- 10 E23.0)”